Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
- Pelzer, Uwe
- Blanc, Jean Frédéric
- Cubillo, Antonio
- Von Hoff, Daniel D
- Wang Gillam, Andrea
- Chen, Li Tzong
- Siveke, Jens T
- Wan, Yin
- Solem, Caitlyn T
- Botteman, Marc F
- Yang, Yoojung
- de Jong, Floris A
- Hubner, Richard A.
- MELISI, Davide
Publication date
January 2017
DOI Publisher
Springer Science and Business Media LLCAbstract
In the NAPOLI-1 Phase 3 trial, nal-IRI+5-fluorouracil and leucovorin (5-FU/LV) significantly improved median overall survival (6.1 vs 4.2 months, P=0.012) and progression-free survival (3.1 vs 1.5 months, P=0.0001) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma patients previously treated with gemcitabine-based therapy. This analysis evaluated between treatment differences in quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST)
Add to ORKG